Objective Every Year, globally ca. 0.8 million people experience reconstructive surgery after mastectomy or lumpectomy and 1.2 million undergo breast augmentation surgery. Currently, breast defects are not properly reconstructed but only temporary filled with silicone implants, which however present several drawbacks such as the need of substitution after approximately 10 years, rupture (30% of incidence), leakage and capsular contracture. An alternative procedure that is currently available in clinics is fat autotransplantation. However, this technique presents potential carcinogenic risks and is still limited to small volumes, requiring multiple interventions to achieve larger reconstructions.REGENERA is an innovative mammary prosthesis based on biodegradable, porous, synthetic biomaterials and manufactured with internal micro-channels replicating the blood-vessels architecture. This distinctive combination, obtained by a patented process, promotes the natural fat growth, and allows the regeneration of a large adipose tissue volume. REGENERA’s overall objective is to improve patients’ quality of life, by restoring permanently the breast’s natural shape, appearance and size following a mastectomy/lumpectomy. Moreover, since REGENERA does not require further surgical operations for the rest of the patient’s life, it can drastically reduce the pain of the patient and decrease the associated Healthcare costs. REGENERA specific objective is to provide a biocompatible support able to induce the ingrowth of adipocytes and subsequently degrade, allowing the complete maturation of a stable adipose tissue, that replaces the original volume occupied by the prosthesis. Fields of science medical and health sciencesclinical medicinesurgerysurgical specialtiesmedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicinesurgerysurgical proceduresmedical and health sciencesmedical biotechnologyimplantsbreast implantsengineering and technologyindustrial biotechnologybiomaterials Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TENSIVE SRL Net EU contribution € 50 000,00 Address Via timavo 34 20124 Milano Italy See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Nord-Ovest Lombardia Milano Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00